By streamlining data ingestion, processing, and analysis for AML research, Elucidata eliminated inefficiencies, ensured seamless scalability, and saved $1.34M in compute costs.

US-based cancer diagnostics company

Anonymized at client request

By building a high-quality dataset using harmonized single-cell and bulk RNA-seq data, Elucidata advanced target discovery and lowered preclinical toxicity risks - with results 7× faster than our internal timeline.

HOOKIPA Pharma

South San Francisco

Elucidata's solutions helped us deepen our understanding of neoantigen-reactive T cells, advancing our T-cell-based anti-tumor therapies. Collaborating with Elucidata enabled crucial insights within six months, offering a clear direction on how to best develop these complex therapeutics

Rubén Alvarez Rodriguez

Head of Research, cTRL Therapeutics

We were looking for public data on a tight deadline to make decisions on our backup targets for solid tumors. Elucidata was able to understand our relevance criteria, identify, and deliver high-quality harmonized data ahead of schedule.

Ming 'Tommy' Tang

Director of Computational Biology, Immunitas Therapeutics

Extremely impressed by Polly and its power to digest and integrate large datasets. The unique partnership that we have allows us to work hand-in-hand with software engineers and scientists to rapidly develop novel hypotheses that we can test in the lab.

Dr. Kate Yen

Founder & CEO, Auron Therapeutics